EUVIMEDEUVIMED entdecken
Crossref

Population Pharmacokinetic‐Based Meropenem Dosing in Critically and Non‐Critically Ill Patients with Mixed Gram‐Negative Bacterial Infections

Shuo Shi, Jie Cui, Guangqing Liu, Jin Gao, Wanjun Bai

Clinical Pharmacology in Drug Development · 2026-06 · 15 (6)

DOI: 10.1002/cpdd.70067 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacology in Drug Development, online erschienen am 04.06.2026. Verfasst von Shuo Shi und 4 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Hebei Medical University, Shijiazhuang, China. Hauptthemen laut MEDLINE: Meropenem, Anti-Bacterial Agents, Gram-Negative Bacterial Infections, Models, Biological. Die Arbeit nennt 40 Literaturangaben. Gefördert von: staff who participated in the study., staff who participated in the study, Hebei Medical University Clinical Pharmacy Young Scholar Support Program - Spark Plan..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study aimed to describe the population pharmacokinetic (PK) of meropenem in patients with mixed Gram‐negative bacterial infections, and further to develop optimal dosing regimens for both non‐critically ill and critically ill patients by combining different pharmacokinetic/pharmacodynamic (PK/PD) targets. Based on retrospectively collected data from patients who underwent therapeutic drug monitoring (TDM) for meropenem, including demographic characteristics, medication records, and laboratory results, a population PK model was developed via nonlinear mixed‐effects modeling. Dosing regimens were subsequently evaluated and provided through Monte Carlo simulation. The population PK analysis of meropenem included 86 steady‐state concentrations from 39 adult patients. The data were modeled using a one‐compartment model. The final model yielded a population typical value for clearance (CL) of 6.10 L/h. Our study showed that estimated glomerular filtration rate (eGFR) significantly affected the PK of meropenem. Monte Carlo simulation results demonstrated that a regimen of 0.5‐h infusion every 8 h was sufficient to achieve the conventional target of 40% ƒ T > MIC in most scenarios. In contrast, achieving the more aggressive target of 100% ƒT > MIC required a regimen of every 6 h; for MIC ≥ 4 mg/L pathogens, this needed to be coupled with an extended infusion time of 3 h. Furthermore, continuous infusion regimens demonstrated a distinct advantage in critically ill patients. This study successfully established a population PK model of meropenem and provided a reference for dosing adjustment based on clinical severity and renal function.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MeropenemAnti-Bacterial AgentsGram-Negative Bacterial InfectionsModels, BiologicalHumansFemaleCritical IllnessMaleMonte Carlo MethodMiddle AgedRetrospective StudiesAgedAdultDrug MonitoringMicrobial Sensitivity TestsInfusions, IntravenousGlomerular Filtration RateDose-Response Relationship, DrugAged, 80 and over

Stichwörter der Autor:innen

Monte Carlo simulationmeropenemmixed Gram‐negative bacterial infectionspopulation pharmacokinetic

Substanzen

MeropenemAnti-Bacterial Agents

Autor:innen und Institutionen

  • College of Pharmacy, Hebei Medical University, Shijiazhuang, China.
  • Department of Pharmacy, Hebei General Hospital, Hebei Key Laboratory of Clinical Pharmacy, Shijiazhuang, Hebei, China.

Förderung

  • staff who participated in the study.
  • staff who participated in the study
  • Hebei Medical University Clinical Pharmacy Young Scholar Support Program - Spark Plan.

Zitieren

APA

Shi, S., Cui, J., Liu, G., Gao, J., & Bai, W. (2026). Population Pharmacokinetic‐Based Meropenem Dosing in Critically and Non‐Critically Ill Patients with Mixed Gram‐Negative Bacterial Infections. Clinical Pharmacology in Drug Development, 15(6). https://doi.org/10.1002/cpdd.70067

Vancouver

Shi S, Cui J, Liu G, Gao J, Bai W. Population Pharmacokinetic‐Based Meropenem Dosing in Critically and Non‐Critically Ill Patients with Mixed Gram‐Negative Bacterial Infections. Clinical Pharmacology in Drug Development. 2026;15(6). doi:10.1002/cpdd.70067

BibTeX
@article{Shi2026,
  author = {Shi, Shuo and Cui, Jie and Liu, Guangqing and Gao, Jin and Bai, Wanjun},
  title = {Population Pharmacokinetic‐Based Meropenem Dosing in Critically and Non‐Critically Ill Patients with Mixed Gram‐Negative Bacterial Infections},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2026},
  volume = {15},
  number = {6},
  doi = {10.1002/cpdd.70067}
}
Kostenlos starten →